DAFNA Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-636,013
| Closed | -$12M | – | 96 |
|
|
2019
Q3 | $12M | Hold |
636,013
| – | – | 4.51% | 3 |
|
|
2019
Q2 | $7.49M | Buy |
636,013
+65,000
| +11% | +$787K | 2.81% | 5 |
|
|
2019
Q1 | $7.79M | Buy |
571,013
+175,000
| +44% | +$2.27M | 3.36% | 5 |
|
|
2018
Q4 | $4.06M | Hold |
396,013
| – | – | 2.02% | 14 |
|
|
2018
Q3 | $6.59M | Hold |
396,013
| – | – | 2.71% | 9 |
|
|
2018
Q2 | $6.26M | Hold |
396,013
| – | – | 2.93% | 7 |
|
|
2018
Q1 | $5.03M | Buy |
396,013
+50,000
| +14% | +$723K | 2.45% | 11 |
|
|
2017
Q4 | $3.96M | Hold |
346,013
| – | – | 2.13% | 16 |
|
|
2017
Q3 | $4.24M | Buy |
346,013
+125,000
| +57% | +$1.3M | 2.63% | 9 |
|
|
2017
Q2 | $2.53M | Hold |
221,013
| – | – | 1.81% | 13 |
|
|
2017
Q1 | $4.6M | Hold |
221,013
| – | – | 3.89% | 4 |
|
|
2016
Q4 | $4.6M | Buy |
221,013
+55,700
| +34% | +$1.45M | 4.04% | 3 |
|
|
2016
Q3 | $5.42M | Hold |
165,313
| – | – | 3.77% | 6 |
|
|
2016
Q2 | $4.13M | Buy |
165,313
+25,000
| +18% | +$676K | 3.27% | 6 |
|
|
2016
Q1 | $3.44M | Buy |
140,313
+122,313
| +680% | +$2.83M | 2.96% | 8 |
|
|
2015
Q4 | $595K | Hold |
18,000
| – | – | 0.53% | 48 |
|
|
2015
Q3 | $590K | Buy |
+18,000
| New | +$765K | 0.59% | 44 |
|
DAFNA Capital Management's ALDR Position: Q4 2019 in Review
DAFNA Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 636,013 shares — an estimated $12M sold.
DAFNA Capital Management first reported a position in ALDR in Q3 2015 and held it in 17 quarters. The position peaked at $12M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- DAFNA Capital Management reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- DAFNA Capital Management sold 636,013 Alder Biopharmaceuticals shares in Q4 2019, an estimated $12M.
- DAFNA Capital Management first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 17 quarters.
- DAFNA Capital Management's Alder Biopharmaceuticals position peaked at $12M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.